COST analysisPROSTATE cancerECONOMIC modelsPROSTATEPROSTATE biopsyObjective: To assess the economic impact of introducing the prostate health index (phi) for prostate cancer (PCa) detection.Methods: A total of 177 patients who presented in an academic institution with a tPSA between 2 and 10ng/ml ...
Prostate Specific Antigen (PSA) test is a blood test useful in screening and diagnosis of prostate cancer or other prostate related disorders. PSA is a chemical made by the prostate gland and is produced by both cancerous and non-cancerous prostate tissues. This test estimates the amount of ...
transrectal ultrasound (TRUS), prostate specific antigen (PSA) and age-related PSA values, gland-volume-adjusted PSA levels, and longitudinal PSA changes were analyzed to identify their cost-effectiveness as prognostic indicators in screening, biopsy, and follow-up of patients with prostate cancer. ...
BACKGROUNDThe Prostate Cancer Prevention Trial (PCPT) demonstrated that finasteride reduces the prevalence of prostate cancer by 24.8% (risk reduction) but questions remain regarding the cost-effectiveness of widespread utilization. The purpose of the current analysis was to evaluate the cost-effectiveness...
Aff ordable cancer care 2 Evidence-informed frameworks for cost-eff ective cancer care and prevention in low , middle, and high-income countries prevention of tobacco-related cancers; secondary prevention of cancers of the cervix, mouth,breast at tertiary care institutions for leadership in research...
Cost-Effectiveness Analysis of SBRT Versus IMRT: An Emerging Initial Radiation Treatment Option for Organ-Confined Prostate Cancer Objectives: The purpose of this study is to compare the cost-effectiveness of 2 external beam radiation therapy techniques for treatment of lowto intermedi... Hodges,JC,...
Prostate-specific antigen (PSA) and prostate health index (PHI) have been used as biomarkers for prostate cancer detection. In this study, we aimed to evaluate the cost-effectiveness of PHI for prostate cancer detection in Chinese men. We developed a Mar
Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate Journal of Clinical OncologyGu X, Choueiri TK, Martin NE, Hu JC, Nguyen PL. Overtreatment of low-risk prostate cancer in the United States: incidence, cost,...
Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost-utility analysis. BJU Int. 2013;111(3):437-450. doi:10.1111/j.1464-410X.2012.11597.x PubMedGoogle ScholarCrossref 31. Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R...
Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients BACKGROUND: The individual risk of recurrence in hormone receptor-positive primary breast cancer patients determines whether adjuvant endocrine therapy sho... PR Blank,M Filipits,P Dubsky...